Immatics NV
NASDAQ:IMTX

Watchlist Manager
Immatics NV Logo
Immatics NV
NASDAQ:IMTX
Watchlist
Price: 5 USD 2.67% Market Closed
Market Cap: 607.8m USD

Operating Margin
Immatics NV

-24.8%
Current
-76%
Average
-5.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-24.8%
=
Operating Profit
-38.6m
/
Revenue
155.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DE
Immatics NV
NASDAQ:IMTX
607.8m USD
-25%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
344.4B USD
29%
US
Amgen Inc
NASDAQ:AMGN
156.2B USD
22%
US
Gilead Sciences Inc
NASDAQ:GILD
132.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.9B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
122.2B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.6B EUR
-1%

Immatics NV
Glance View

Market Cap
607.8m USD
Industry
Biotechnology

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 188 full-time employees. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

IMTX Intrinsic Value
5.31 USD
Undervaluation 6%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-24.8%
=
Operating Profit
-38.6m
/
Revenue
155.8m
What is the Operating Margin of Immatics NV?

Based on Immatics NV's most recent financial statements, the company has Operating Margin of -24.8%.

Back to Top